Britannia Life Sciences Inc.
BLAB
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -64.39% | 483.03% | 657.64% | 1,199.54% | 500.64% |
| Total Depreciation and Amortization | -21.25% | 2.76% | -38.08% | -61.36% | -71.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 84.17% | -736.05% | -2,608.61% | -875.90% | -856.51% |
| Change in Net Operating Assets | -382.06% | -139.98% | -100.98% | -87.97% | -31.36% |
| Cash from Operations | 14.26% | -530.65% | -521.00% | -340.14% | -216.56% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -153.08% | 1,840.26% | 2,597.00% | 7,955.73% | 26,791.45% |
| Cash from Investing | -153.08% | 1,161.63% | 463.46% | 952.73% | 775.51% |
| Total Debt Issued | -- | 32.77% | 17.84% | -- | -- |
| Total Debt Repaid | 92.32% | -1,524.33% | -112.43% | -13.95% | 21.89% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 88.40% | 29.97% | -159.18% | -- |
| Cash from Financing | 92.94% | 79.43% | 33.36% | 66.15% | 40.73% |
| Foreign Exchange rate Adjustments | -99.06% | -125.72% | -114.32% | 154.03% | 125.53% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -219.53% | 45.82% | 75.32% | 415.93% | 582.13% |